Table 5. 1: Total number of samples attempted to be sequenced and total samples considered for downstream analysis

|  |  |  |
| --- | --- | --- |
| Sequencing Method | Total attempted to be sequence | Total samples with PR and RT |
| Consensus | 349 | 349 |
| FLX | 630 | 599 |
| Junior | 471 | 468 |

Table 5. 2: Number of samples with and without previous PMTCT exposure that are sequenced in two or more sequencing methods

|  |  |  |  |
| --- | --- | --- | --- |
|  | Consensus and FLX | Consensus and Junior | FLX and Junior |
| Number of PMTCT samples | 126 | 104 | 146 |
| Number of non-PMTCT samples | 201 | 153 | 318 |
| Total | 327 | 257 | 464 |

**Table 5.3: Prediction of nevirapine resistance significantly correlates with the time of nevirapine exposure**

|  |  |  |  |
| --- | --- | --- | --- |
| Median days since NVP exposure | | | |
| ***Prevalence*** | ***Sensitive*** | ***Resistant*** | ***p-value*** |
| 20 | 661.5 | 178 | 0.1711 |
| 15 | 661.5 | 136 | **0.04492** |
| 10 | 660 | 136 | **0.03447** |
| 5 | 663 | 193 | **0.006021** |
| 1 | 711 | 221.5 | **0.0005366** |